<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116632</url>
  </required_header>
  <id_info>
    <org_study_id>MB006-017</org_study_id>
    <nct_id>NCT04116632</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults</brief_title>
  <official_title>A Multiple Dose Pharmacokinetic/Pharmacodynamic and Safety and Tolerability Study of BMS-963272 in Obese But Otherwise Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and tolerability of multiple doses of BMS-963272 in obese
      but otherwise healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Actual">February 10, 2020</completion_date>
  <primary_completion_date type="Actual">February 10, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration of BMS-963272 (Cmax)</measure>
    <time_frame>Day 1, Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum observed concentration of BMS-963272 (Tmax)</measure>
    <time_frame>Day 1, Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUC(TAU))</measure>
    <time_frame>Day 1, Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total clearance of the drug from plasma after oral administration (CLss/F)</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss/F)</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration at steady state (Cavg,ss)</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (T-HALF)</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation index (AI)</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate elimination constant (kel) of BMS-963272</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of triglycerides (TG) and fatty acids in response to the oral lipid tolerance test (oLTT)</measure>
    <time_frame>Day 7, Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incremental AUC (iAUC) of TG and fatty acids in response to the oLTT</measure>
    <time_frame>Day 7, Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 55 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 55 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes in vital signs, electrocardiograms (ECGs), physical examinations and clinical laboratory tests</measure>
    <time_frame>Up to 55 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Obese But Otherwise Healthy Participants</condition>
  <arm_group>
    <arm_group_label>BMS-963272 or Placebo once daily (QD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-963272 or Placebo every 12 hours (Q12H)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-963272 or Placebo every 8 hours (Q8H)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-963272</intervention_name>
    <description>Single dose with varying frequency among groups</description>
    <arm_group_label>BMS-963272 or Placebo every 12 hours (Q12H)</arm_group_label>
    <arm_group_label>BMS-963272 or Placebo every 8 hours (Q8H)</arm_group_label>
    <arm_group_label>BMS-963272 or Placebo once daily (QD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>BMS-963272 or Placebo every 12 hours (Q12H)</arm_group_label>
    <arm_group_label>BMS-963272 or Placebo every 8 hours (Q8H)</arm_group_label>
    <arm_group_label>BMS-963272 or Placebo once daily (QD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Participants must be in good general health, in the opinion of the investigator, with
             no clinically significant deviation from normal in medical history, physical
             examination findings, ECGs, or laboratory results.

          -  Participants must have a BMI of 30 kg/m2 to 40 kg/m2 inclusive

          -  Women (not of childbearing potential) and men aged 18 to 60 years, inclusive

        Exclusion Criteria:

          -  Previous participation in the current study

          -  Inability or unwillingness to comply with protocol-defined restrictions or
             requirements regarding lifestyle, diet, concomitant medications, or other aspects of
             the study

          -  Inability to tolerate the oLTT meal or to comply with oLTT testing conditions

          -  Inability to tolerate oral medication

          -  Inability to tolerate venipuncture and/or inadequate venous access

          -  Women who are breastfeeding

          -  Medical Conditions

          -  History of lactose intolerance

          -  Any significant (in the opinion of the investigator) acute or chronic illness

          -  Type 1 or 2 diabetes

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG, or clinical laboratory determinations beyond
             what is consistent with the target population

          -  Previous/Concomitant Therapy

          -  Previous exposure to BMS-963272

        Other protocol-defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences - Lenexa</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

